Payment overview · 2025
General Payments
$28,561.13
37 reported records · 5 companies
Healthcare provider profile · identity verified
David Robert Brown, MD, PHD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · ROCKVILLE, MD · NPI 1114044906
Verified facts
What the public records show
CMS Open Payments records show David Robert Brown, MD, PHD received $28,561.13 in general payments during 2025 across 37 reported records.
Corcept Therapeutics accounted for 98.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Korlym, Tymlos.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Korlym by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $28,097.54 | 98.4% | 33 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $144.19 | 0.5% | 1 | 2025 |
| AERIN MEDICAL INC. | Unresolved — no canonical attribution shown | $143.84 | 0.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $125.00 | 0.4% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $50.56 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,093.00 | 6 |
| Honoraria | $8,218.00 | 3 |
| Consulting Fee | $5,567.50 | 2 |
| Travel and Lodging | $3,603.52 | 12 |
| Food and Beverage | $1,079.11 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $28,097.54 | 33 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $144.19 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $144.19 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $144.19 | 1 | 2025 |
Source payment records
|
|||||
| RHINAER STYLUS Normalized: rhinaer stylus |
Device | AERIN MEDICAL INC. | $143.84 | 1 | 2025 |
Source payment records
|
|||||
| VIVAER STYLUS Normalized: vivaer stylus |
Device | AERIN MEDICAL INC. | $143.84 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $50.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Korlym korlym |
2025 | Korlym | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ezetimibe | Ezetimibe | 215 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 147 | 34 |
| Synthroid | Levothyroxine Sodium | 114 | 21 |
| Atorvastatin Calcium | Atorvastatin Calcium | 110 | 37 |
| Ozempic | Semaglutide | 109 | 24 |
| Mounjaro | Tirzepatide | 76 | 18 |
| Metformin Hcl Er | Metformin Hcl | 70 | 19 |
| Korlym | Mifepristone | 59 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 47 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 45 | 12 |
| Vascepa | Icosapent Ethyl | 42 | suppressed |
| Metformin Hcl | Metformin Hcl | 39 | 11 |
| Lisinopril | Lisinopril | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | 11 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 12 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Tymlos | Abaloparatide | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Losartan Potassium | Losartan Potassium | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $28,561.13 · 37 records | Corcept Therapeutics | DEXCOM G7 GSS (161), Korlym, RHINAER STYLUS, Tymlos, VIVAER STYLUS, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Korlym play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Corcept Therapeutics?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error